【2022 ASH】问鼎世界之巅，40篇中国研究入选Oral，尽显中国学术风范

第64届美国血液学年会（ASH）将以线下（美国新奥尔良）及线上的形式召开。ASH作为全世界血液学工作者的盛会，每年都会公布和发表世界各国的最新血液学进展。届时将汇集各国知名血液病学专家，分享全球最前沿的研究进展和突破性临床数据。

ASH摘要公布，我们第一时间检索出40篇中国专家在本届ASH的Oral Presentation，中国研究再度唱响世界的舞台！让我们一起来享受这场饕餮盛宴吧~

1Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China

中文标题：CAR-T 细胞治疗的持续缓解和相关不良事件严重程度降低：CNCT19（inaticabtagene autoleucel）治疗中国 R/R B-ALL 成人患者的关键性研究报告

摘要号：660

报告人：Jianxiang Wang 类型：Oral and Poster Abstracts

2A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

中文标题：新型第三代 BCR-ABL 酪氨酸激酶抑制剂（TKI）奥雷巴替尼在中国 TKI 耐药 CML 患者中的安全性和疗效的 5 年随访研究

摘要号：81

报告人：Qian Jiang

类型：Oral and Poster Abstracts

3Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

中文标题：在 AP-CML 患者中，与伊马替尼相比，二代酪氨酸激酶抑制剂的初始治疗是否更优：一项多中心回顾性研究

摘要号：335

报告人：Sen Yang

类型：Oral and Poster Abstracts

4Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation 

中文标题：奥雷巴替尼治疗 T315I 突变 TKI 耐药 AP-CML 和 CP-CML 患者的关键 II 期试验结果

摘要号：83

报告人：Qian Jiang

类型：Oral and Poster Abstracts

5High Dimensional Mapping of Bone Marrow Immune Characteristics in Immune Thrombocytopenia

中文标题：免疫性血小板减少症中骨髓免疫特征的高维映射

摘要号：914

报告人：Feng-Qi Liu

类型：Oral and Poster Abstracts

6Results from the First Phase 3 Crovalimab (C5 Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

中文标题：COMMODORE 3 试验 III 期结果：Crovalimab（C5抑制剂）在未接受过补体抑制剂治疗的阵发性夜间血红蛋白尿（PNH）患者中的疗效和安全性

摘要号：293

报告人：Rong Fu

类型：Oral and Poster Abstracts

7Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

中文标题：维奈克拉+去甲基化药物在复发难治性急性髓系白血病中遗传特征与疗效的相关性

摘要号：837

报告人：Guangyang Weng

类型：Oral and Poster Abstracts

8Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker

中文标题：奥布替尼、利妥昔单抗和大剂量甲氨蝶呤（HD-MTX）治疗初治 PCNSL 的疗效、安全性和生物标志物的回顾性分析

摘要号：558

报告人：Wenrong Huang

类型：Oral and Poster Abstracts

9MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB

中文标题：CAR-T 细胞中的 MEK 抑制通过下调 C-Fos 和 JunB 防止清除和终末分化

摘要号：253

报告人：Xiujian Wang

类型：Oral and Poster Abstracts

10Predictive Factors of Relapse for Primary Immune Thrombocytopenia in Adults: A Single-Center Retrospective Cohort Analysis

中文标题：成人原发性免疫性血小板减少症复发的预测因素：单中心回顾性分析

摘要号：918

报告人：Xiyan Wang

类型：Oral and Poster Abstracts

11Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

中文标题：信迪利单抗联合 P-Gemox（培门冬酶、吉西他滨和奥沙利铂）方案治疗新诊断晚期、结外 NK/T 细胞淋巴瘤（鼻型）：一项多中心、II 期、开放性、Spirit 研究

摘要号：955

报告人：Qingqing Cai

类型：Oral and Poster Abstracts

12Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia

中文标题：磷酸化稳定的 TET1 作为 B 细胞急性淋巴细胞白血病的癌蛋白和治疗靶点

摘要号：415

报告人：Zhenhua Chen

类型：Oral and Poster Abstracts

13Prospective Evaluation of Sorafenib Combined with Chemotherapy in Newly Diagnosed Adult Core-Binding Factor Acute Myeloid Leukemia: An Open-Label, Randomized Controlled, Multicenter Phase II Trial 

中文标题：索拉非尼联合化疗治疗新诊断成人核心结合因子相关急性髓系白血病的前瞻性评估：一项开放性、随机对照、多中心 II 期试验

摘要号：830

报告人：Pengcheng Shi

类型：Oral and Poster Abstracts

14Development and Validation of a Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

中文标题：基于成人患者异基因造血干细胞移植后心力衰竭临床生物标志物的预后模型的开发和验证

摘要号：780

报告人：Aobei Zhang

类型：Oral and Poster Abstracts

15Single Cell Analysis Highlights Th17-Polarized CD4+ Naive T Cells with JAK3/STAT3 Pathway Activation in Pediatric Severe Aplastic Anemia

中文标题：单细胞分析强调了 Th17 极化 CD4 + 幼稚 T 细胞与 JAK3/STAT3 通路活化在儿童重度再生障碍性贫血中的作用

摘要号：195

报告人：Jingliao Zhang

类型：Oral and Poster Abstracts

16Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

中文标题：两种预处理方式对接受异基因造血细胞移植的骨髓增生异常综合征和继发性急性髓系白血病复发的影响

摘要号：989

报告人：Li Xuan

类型：Oral and Poster Abstracts

17Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies

中文标题：自噬触发 B 细胞恶性肿瘤中 CAR-T 细胞介导的细胞毒性的癌症免疫逃避

摘要号：257

报告人：Lu Tang

类型：Oral and Poster Abstracts

18Validation of the 5th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

中文标题：在单中心 852 例初治患者中验证第 5 版世界卫生组织骨髓增生异常肿瘤分类

摘要号：560

报告人：Yudi Zhang

类型：Oral and Poster Abstracts

19Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)

中文标题：通过流式细胞术检测早期可测量微小残留病（MRD）对新发急性髓系白血病（AML）的预后影响和临床应用

摘要号：839

报告人：Congxiao Zhang

类型：Oral and Poster Abstracts

20Basiliximab in the Prevention of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Major: A Prospective, Multicenter, Open-Label, Randomized Controlled Study

中文标题：巴利昔单抗预防重型地中海贫血患者非亲缘供者造血干细胞移植后 aGVHD：一项前瞻性、多中心、开放性、随机对照研究

摘要号：575

报告人：Rongrong Liu

类型：Oral and Poster Abstracts

21Development and Validation of a Multiple Factor-Based Prognostic Score System of Thrombosis in Polycythemia Vera (MFPS-PV)

中文标题：基于多因素分析的真性红细胞增多症血栓预后评分系统（MFPS-PV）的开发和验证

摘要号：338

报告人：Gu Wenjing

类型：Oral and Poster Abstracts

22Mutation Spectrum of FLT3 and Significance of Non–Canonical FLT3 Mutations in Hematological Malignancies

中文标题：血液系统恶性肿瘤中 FLT3 突变谱和非典型 FLT3 突变的意义

摘要号：595

报告人：Shengli Xue

类型：Oral and Poster Abstracts

23Erythrocyte Sphingosine 1 Phosphate Is Essential to Combat HIF1α-Dependent Creatine Shuttle, Macrophage Polarization and Fibrosis

中文标题：红细胞鞘氨醇 1 磷酸盐对于抗 HIF1α 依赖性肌酸穿梭、巨噬细胞极化和纤维化至关重要

摘要号：17

报告人：Tingting Xie

类型：Oral and Poster Abstracts

24Oral Realgar-Indigo Naturalis Formula Versus Intravenous Arsenic Trioxide for Non-High-Risk Patients with Acute Promyelocytic Leukemia: Interim Results of a Multicenter Randomized Controlled Trial APL16

中文标题：比较口服雄黄靛蓝制剂与静脉注射三氧化二砷治疗非高危急性早幼粒细胞白血病患者一项多中心随机对照试验 APL16 的中期结果

摘要号：833

报告人：Huaiyu Wang

类型：Oral and Poster Abstracts

25Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial

中文标题：基于人源间充质干细胞引导围产期 MSC 的细胞疗法治疗脾切除术后无反应的难治性免疫性血小板减少症的多组学分析：一项 I 期临床试验

摘要号：816

报告人：Yuchen Gao

类型：Oral and Poster Abstracts

26Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

中文标题：BCMA/CD19 双靶 FasTCAR-T 细胞（GC012F）作为适合移植的新诊断高危多发性骨髓瘤的一线治疗的 I 期、开放性、单臂研究

摘要号：366

报告人：Juan Du

类型：Oral and Poster Abstracts

27CD58 Could be As a Leukemic Marker in Relapsed/Refractory B-ALL Patients after Multiline Therapies

中文标题：CD58 可作为多线治疗后复发/难治性 B-ALL 患者的白血病标志物

摘要号：434

报告人：Xinjian Yu

类型：Oral and Poster Abstracts

28Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

中文标题：CD7 CAR-T 细胞治疗 53 例复发或难治性（R/R）T 细胞急性淋巴细胞白血病（T-ALL）和 T 细胞淋巴母细胞淋巴瘤（T-LBL）患者分析

摘要号：980

报告人：Peihua Lu

类型：Oral and Poster Abstracts

29Addition of Ruxolitinb to Corticosteroids As First-Line Therapy for High-Risk Acute Graft Versus Host Disease in Allogeneic Peripheral Blood Stem Cell Transplantation

中文标题：在皮质类固醇基础上加用芦可替尼作为异基因外周血干细胞移植中高危急性移植物抗宿主病的一线治疗

摘要号：574

报告人：Daihong Liu

类型：Oral and Poster Abstracts

30BRD9 Facilitates Oncogenic Nrf2 Pathway and Dampens Venetoclax Sensitivity By Remodeling Chromatin Accessibility in Chronic Lymphocytic Leukemia

中文标题：BRD9 在慢性淋巴细胞白血病中通过重塑染色质可及性促进致癌 Nrf2 通路并抑制维奈克拉敏感性

摘要号：146

报告人：Xinting Hu

类型：Oral and Poster Abstracts

31Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies

中文标题：双靶点 CD22/CD19 CAR-T 的结构优化及其对 B 细胞恶性肿瘤的抗肿瘤作用

摘要号：255

报告人：Yu Zhang

类型：Oral and Poster Abstracts

32Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

中文标题：维奈克拉联合地西他滨治疗新诊断 ELN 不良预后急性髓系白血病年轻成人患者：一项 II 期试验更新结果

摘要号：601

报告人：Jundan Xie

类型：Oral and Poster Abstracts

33PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

中文标题：PHF19 通过促进免疫抑制微环境抑制多发性骨髓瘤细胞对免疫治疗的反应

摘要号：350

报告人：Tengteng Yu

类型：Oral and Poster Abstracts

34Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms

中文标题：造血细胞和成纤维细胞亚群之间的交互对话驱动骨髓增殖性肿瘤中骨髓微环境的炎症和重塑

摘要号：453

报告人：Rong Li

类型：Oral and Poster Abstracts

35Homoharringtonine Exhibits Anti-Tumor Effect in T-Cell Acute Lymphoblastic Leukemia By Targeting Notch1/Myc Pathway

中文标题：高三尖杉酯碱通过靶向 Notch1/Myc 通路在 T 细胞急性淋巴细胞白血病中表现出抗肿瘤作用

摘要号：149

报告人：Shanshan Suo

类型：Oral and Poster Abstracts

36Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed

中文标题：高三尖杉酯碱与维奈克拉对早期 T 细胞祖细胞急性淋巴细胞白血病的高度协同作用：从实验室到临床

摘要号：942

报告人：Shanshan Suo

类型：Oral and Poster Abstracts

37Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma

中文标题：通过全基因组 CRISPR-Cas9 筛选确定 KDM6A 是多发性骨髓瘤中达雷妥尤单抗敏感性调节剂

摘要号：148

报告人：Jiye Liu

类型：Oral and Poster Abstracts

38Immunotyping of ITP Based on Different Platelet Destruction Mechanism Are Associated with Response to Splenectomy

中文标题：基于不同血小板破坏机制的 ITP 免疫分型与脾切除术应答相关

摘要号：916

报告人：Hui Yuan Li

类型：Oral and Poster Abstracts

39

Obesity Is Associated with Adverse Outcomes in Primary Immune Thrombocytopenia

中文标题：肥胖与原发性免疫性血小板减少症的不良预后相关

摘要号：20

报告人：Zhengrui Xiao

类型：Oral and Poster Abstracts

40Demonstration That Loss of TET2 Impairs DNA Mismatch Repair Resulting in Clonally Restricted Genomic Instability

中文标题：TET2 缺失会损害 DNA 错配修复，导致克隆限制性基因组不稳定性

摘要号：823

报告人：Dongxu Jiang

类型：Oral and Poster Abstracts

作者 | 书女

内容来源 | Htology血液前沿